Allicin

DB11780InvestigationalSmall molecule

Allicin has been used in trials studying the treatment of Follicular Lymphoma.

Mechanism: Pharmacologically active on Acetylcholinesterase, Transient receptor potential cation channel subfamily V member 1, and Transient receptor potential cation channel subfamily A member 1
Curator reviewed
Formula / weight: C₆H₁₀OS₂ · 162.273 g/mol (avg)

Resolves to

Compound

UNII3C39BY17Y6CAS539-86-6ChEMBLCHEMBL359965ChEBI28411PubChem65036KEGGC07600

Clinical / RWD

RxNorm2729790

Structure

InChIKeyJDLKFOPOAOFWQN-UHFFFAOYSA-NSMILESC=CCSS(=O)CC=C

Targets

P22303ACHEQ8NER1TRPV1O75762TRPA1P06276BCHE

Transporters

P08183ABCB1

What you can answer from here — as of July 07, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

609Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Allicin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In